LS-170

LS-170 is a YEATS2 YEATS domain inhibitor with an IC₅₀ of 0.14 μM. LS-170 displays selectivity for the YEATS2 YEATS domain over other YEATS domain family members and other epigenetic 'reader' and 'eraser' proteins. LS-170 reduces chromatin occupancy of the Ada-two-A-containing (ATAC) complex, decreases ATAC -dependent histone acetylation levels, and downregulates expression of ATAC -governed genes. LS-170 suppresses tumor growth in a lung cancer mouse model. LS-170 can be used for the research of non-small cell lung cancer ^[1].

In Vivo, Nanoparticles loaded with LS-170 (6 mg/kg; intravenous injection; once every 4 days; for 14 days) significantly inhibit tumor growth of non-small cell lung cancer in mice by suppressing the ATAC complex^[1].

In Vitro, LS-170 (0.14 μM) selectively inhibits the YEATS2 YEATS domain with an IC₅₀ of 0.14 μM without affecting other YEATS domains or epigenetic reader/eraser proteins^[1]. LS-170 (20 μM; 24 h) selectively dissociates YEATS2 from chromatin in U2OS cells without affecting other YEATS domain proteins^[1]. LS-170 (20 μM) selectively targets the ATAC complex (YEATS2 and MBIP subunits) in H1299 cells^[1]. LS-170 (20 μM; 24 h) displaces YEATS2 from chromatin at ATAC-bound gene promoters in H1299 cells^[1]. LS-170 reduces ATAC-dependent histone acetylation marks (H3K9ac, H3K14ac, H3K27ac) in H1299 cells without altering YEATS2 expression^[1]. LS-170 (20 μM; 24 h) downregulates ATAC-governed genes involved in DNA replication and cell cycle in H1299 cells^[1]. LS-170 (72 h) inhibits the growth of NSCLC cell lines with GI50 values ranging from 6.8 μM (H157) to 29.0 μM (A549)^[1]. LS-170 (20 μM; 14 days) inhibits colony formation in H1299, A549, and PC9 NSCLC cells^[1].

References:
[1]. Liu S, et al. Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex. Nat Chem Biol. Published online January 9, 2026.